End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
40.86 EUR | -1.49% | -.--% | +2.97% |
06-26 | Demant Flags Delay in Completion of Communications Business' Strategic Review | MT |
05-29 | UK’s Competition Regulator Closes Cochlear-Demant Deal | MT |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an enterprise value anticipated at 3.41 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.97% | 9.43B | - | ||
-17.92% | 19.75B | B | ||
+8.13% | 14.51B | B | ||
-23.29% | 1.91B | - | ||
+7.47% | 1.81B | B+ | ||
+0.35% | 1.23B | D- | ||
-.--% | 521M | - | ||
-.--% | 368M | - | - | |
+101.20% | 233M | - | ||
+20.04% | 100M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DEMANT Stock
- DEMA Stock
- Ratings Demant A/S